Collegium Pharmaceutical Inc diskutieren
Collegium Pharmaceutical Inc
WKN: A14SUV / Name: Collegium Pharm / Aktie / Pharmazeutika / Small Cap /
34,20 €
-1,16 %
Healthcare | Drogen - Generic | USA
(Vom Mitglied beendet)
| Drogen - Generic | Vereinigtes Königreich
hat $
(Vom Mitglied beendet)
Xtampza ER (Oxycodon) Starke Schmerzen
Submission ADND angekündigt 5. Oktober 2016, so dass ein PDUFA Datum 4. August 2017 - dreimonatige Verlängerung festgestellt - neues Datum PDUFA etwa 4. November 2017.
(Zielkurs erreicht)
Collegium in a huge potential market and solid operational momentum
Collegium continues to see a nice ramp-up in sales of Xtampza.
First-quarter revenues should be very strong as well, as regulatory action following the opioid crisis could make Xtampza a big winner.
30$
auf Sicht von 12 Mon.
marge stimmt der Buy-Einschätzung von tamam zu
marge stimmt am 03.05.2019 der Buy-Einschätzung von tamam mit dem Kursziel 40$ zu.
Überschrift: Collegium in a huge potential market and solid operational momentum
(Vom Mitglied beendet)
(Vom Mitglied beendet)
Buy Collegium Pharmaceutical Inc
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Collegium Pharmaceutical with a $33.83 average price target.
Collegium Pharmaceutical, Inc. operates as a pharmaceutical company, which engages in the developing and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. Its products include Xtampza ER, Nucynta ER and Nucynta IR. The Xtampza ER provides pain control while maintaining its extended-release drug release profile after being subjected to common methods of abuse and accidental misuse. The Nucynta ER for the treatment of chronic pain and neuropathic pain associated with diabetic peripheral neuropathy. The Nucynta IR is a release formulation of tapentadol indicated for the management of acute pain severe enough to require an opioid analgesic. The company was founded by Michael Thomas Heffernan in October 2003 and is headquartered in Stoughton, MA.
Collegium Pharmaceutical, Inc. operates as a pharmaceutical company, which engages in the developing and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. Its products include Xtampza ER, Nucynta ER and Nucynta IR. The Xtampza ER provides pain control while maintaining its extended-release drug release profile after being subjected to common methods of abuse and accidental misuse. The Nucynta ER for the treatment of chronic pain and neuropathic pain associated with diabetic peripheral neuropathy. The Nucynta IR is a release formulation of tapentadol indicated for the management of acute pain severe enough to require an opioid analgesic. The company was founded by Michael Thomas Heffernan in October 2003 and is headquartered in Stoughton, MA.
Buy Collegium Pharmaceutical Inc
Buy Collegium Pharmaceutical Inc
Buy Collegium Pharmaceutical Inc
Kursziel geändert auf 24,746
Sell Collegium Pharmaceutical Inc
Neueste Beiträge
Joe130978 in Datadog Inc. diskutieren